Nephros (NEPH) Q2 2024 earnings summary

Executive summary

• Q2 2024 net revenue declined 8% year-over-year to $3.3 million, mainly due to a 92% drop in emergency response revenue, while programmatic business grew 8% and over 300 new customers were added in the past 12 months.

• Net loss for Q2 2024 improved to $289,000 from $433,000 in Q2 2023, reflecting cost controls and focus on profitability.

• Gross margin remained stable at 59% in Q2 2024, supported by improved programmatic sales and cost management.

• Strategic initiatives include digital tool expansion, targeting new sectors, and developing automatic replenishment models.

• The company continues to focus on medical and commercial water filtration markets, with recurring sales growth and ongoing product development.

Financial highlights

• Q2 2024 net revenue was $3.3 million, down from $3.5 million in Q2 2023, with gross margin steady at 59%.

• Net loss for Q2 2024 improved to $289,000 from $433,000 in Q2 2023.

• Adjusted EBITDA loss improved to $133,000 from $183,000 in the prior year period.

• Cash and cash equivalents were $3.1 million as of June 30, 2024, down from $4.3 million at year-end 2023.

• For the first half of 2024, sales declined 6% year-over-year, but excluding emergency response, sales rose 10%.

Outlook and guidance

• Management anticipates a potential rebound in emergency response business due to new regulatory requirements in Ohio and New Jersey starting October 2024.

• Focus remains on long-term growth, profitability, and expanding into new markets such as dental and sterile processing.

• Filter tracking app rollout is ongoing, with full implementation expected by Q1 or Q2 2025.

• Current cash balances and operational focus are believed sufficient to fund the operating plan for at least the next 12 months.

• If operating results fall short, further cost reductions may be implemented.